scholarly journals Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis

2019 ◽  
Vol 6 (1) ◽  
pp. 17-58 ◽  
Author(s):  
Bert A. 't Hart

Abstract. Aging Western societies are facing an increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) for which treatments that are safe and effective are scarce. One of the main reasons for this situation is the lack of animal models, which accurately replicate clinical and pathological aspects of the human diseases. One important AIMID is the neuroinflammatory disease multiple sclerosis (MS), for which the mouse experimental autoimmune encephalomyelitis (EAE) model has been frequently used in preclinical research. Despite some successes, there is a long list of experimental treatments that have failed to reproduce promising effects observed in murine EAE models when they were tested in the clinic. This frustrating situation indicates a wide validity gap between mouse EAE and MS. This monography describes the development of an EAE model in nonhuman primates, which may help to bridge the gap.

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Mir Hadi Jazayeri ◽  
Khadijeh barzaman ◽  
Reza Nedaeinia ◽  
Tayebe Aghaie ◽  
Morteza Motallebnezhad

Abstract Background Different studies have demonstrated the anti-inflammatory effects of human placental extract both in vivo and in vitro. Considering the chronic inflammatory nature of multiple sclerosis (MS) disease, we examined whether or not the administration of human placental extract is able to attenuate the neurological symptoms detected in experimental autoimmune encephalomyelitis (EAE) model of MS. Methods The injected myelin oligodendrocyte glycoprotein (MOG) induced EAE in mice, and treatment began from day 4 post-injection by intraperitoneal administration of 0.2 mg/kg human placental extract, repeated every other day up to day 31 post-injection. At the end of the treatment, luxol fast blue (LBS) staining and hematoxylin and eosin (H&E) staining were performed to evaluate the demyelination of neurons and inflammatory responses, respectively. Further assessed were the serum concentrations of IL-23 and IL-27. Results The administration of human placental extract was able to significantly reduce the mean clinical score in EAE mice, decrease the pro-inflammatory process and attenuate neural demyelination. Moreover, while the serum concentration of IL-23 was significantly diminished in the EAE mice receiving human placental extract compared to the non-treated EAE group, IL-27 concentration was significantly increased. Conclusions Our findings demonstrated the administration of human placental extract could significantly attenuate the neurological symptoms in the EAE model of MS in part through modulating the serum levels of IL-23 and IL-27 and enhancing neuroprotection and myelin repair.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 858-858
Author(s):  
Eric S. Mullins ◽  
Kathryn E. Talmage ◽  
Keith W. Kombrinck ◽  
Whitney M Miller ◽  
Joseph S. Palumbo ◽  
...  

Abstract Abstract 858 Multiple sclerosis (MS) is an inflammatory disease characterized by autoimmune demyelination of neurons and axonal damage within the central nervous system, leading to relapsing/remitting neurological deficits, including sensory and motor deficits. MS plaques are characterized by blood-brain barrier disruption leading to perivascular deposition of fibrin that correlates with areas of microglia activation and myelin damage. Consistent with multiple studies showing that hemostatic factors can serve as important modulators of the inflammatory response in vivo, fibrin(ogen) has been identified as a novel regulator of microglial activation and differentiation. Furthermore, fibrin(ogen) has been found, via the αMβ2 binding motif on the γ chain, to play a role in microglial activation in experimental autoimmune encephalomyelitis (EAE), a murine model of MS. However, previous work by our lab, as well as others, suggests that thrombin-mediated proteolysis plays a greater role in driving neuroinflammatory disease than by merely supporting fibrin formation. Our working hypothesis is that thrombin-mediated proteolysis drives autoimmune neuroinflammation through both fibrin(ogen)-dependent and fibrin(ogen)-independent pathways. To test this hypothesis, we have initiated studies of EAE in mice lacking selected thrombin substrates, including protease activated receptors (PARs) and factor XIII (fXIII). Clinical evaluation of loss of motor function in EAE-challenged cohorts of PAR-1-deficient, PAR-4-deficient and WT control mice revealed a similar outcome in all three cohorts, suggesting PARs may have either a modest or a secondary role in EAE-induced neuroinflammatory disease. However, mice with a constitutive deficiency of another thrombin substrate, the fibrin cross-linking transglutaminase fXIII, were found to have a significant amelioration in motor function loss when challenged with EAE. To further explore this phenotype, we have utilized cystamine, a transglutaminase inhibitor, as a pharmacologic complement to the fXIII knockout mice. Mice with cystamine placed in their drinking water during the EAE challenge period also experienced significantly less disease than control mice that did not receive cystamine. This data suggests that (pro)thrombin contributes neuroinflammatory disease by both supporting local fibrinogen polymerization and by activation of fXIII leading to fibrin stabilization. Furthermore, this line of research suggests that more detailed studies of fXIII may reveal novel strategies for limiting or reversing the devastating pathologies associated with multiple sclerosis. Disclosures: Mullins: Baxter: Consultancy. Palumbo:Novo Nordisk Corporation: Research Funding.


2005 ◽  
Vol 202 (1) ◽  
pp. 4-4 ◽  
Author(s):  
Heather L. Van Epps

In the early 1930s, Thomas Rivers and colleagues provided the first evidence that immune cells can attack the brain. Their simple experiments established what is now the most well-studied model of autoimmunity—the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.


2011 ◽  
Vol 69 (6) ◽  
pp. 938-942 ◽  
Author(s):  
David Henrique Rodrigues ◽  
Márcia de Carvalho Vilela ◽  
Norinne Lacerda-Queiroz ◽  
Aline Silva de Miranda ◽  
Larissa Fonseca da Cunha Sousa ◽  
...  

Multiple sclerosis is a neuroinflammatory disease that results in serious neurological disability. Besides physical impairment, behavioral symptoms are also common in patients with multiple sclerosis. Experimental autoimmune encephalomyelitis (EAE) is considered to be a model of multiple sclerosis and mimics the main features of the disease, such as demyelination and motor impairment. In this work, we aimed to study behavioral parameters in animals with EAE using the MOG35-55 model in C57BL/6 mice. We analyzed memory and anxiety in animals using the elevated plus maze, the step down inhibitory avoidance task and the memory recognition test. No differences in any tests were found when comparing controls and animals induced with EAE. Therefore, we conclude that behavioral changes in animals with EAE induced with MOG35-55 are probably subtle or absent.


2006 ◽  
Vol 12 (4) ◽  
pp. 369-374 ◽  
Author(s):  
D Merkler ◽  
B Schmelting ◽  
B Czéh ◽  
E Fuchs ◽  
C Stadelmann ◽  
...  

Pathomorphological studies described pathological heterogeneity in patients with multiple sclerosis (MS). Different effector mechanisms might therefore be responsible for lesion formation in MS. The present report shows that myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) in common marmoset monkeys reflects one specific lesional subtype of MS, namely MS pattern II lesions with antibody/complement-mediated damage. MOG-induced EAE in marmoset monkeys will, therefore, provide an ideal model for therapeutic approaches directed against B-cell/antibody/complement in MS.


Sign in / Sign up

Export Citation Format

Share Document